ArticleFrontiers in immunology2025

HPK1 kinase inhibitor: a sufficient approach to target HPK1 to modulate T cell activation in cancer immunotherapy compared with degraders.

Qin Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.